Fig. 7: HI-TOPK-032 inhibits EC growth in vivo. | Cell Death & Disease

Fig. 7: HI-TOPK-032 inhibits EC growth in vivo.

From: TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway

Fig. 7

a, d Representative tumor images of HEG51 (a) and LEG110 (d) after HI-TOPK-032 treatment. b, e Tumor volumes of HEG51 (b) and LEG110 (e) were recorded every two days. Tumor growth curve of each group was shown. c, f Analysis of tumor weights in HEG51 (c) and LEG110 (f) after HI-TOPK-032 treatment. g, h Representative tumor images and statistical analysis of IHC positive staining of Ki67 in HEG51 (g) and LEG110 (h) tumor tissue slices. i, j The phosphorylation levels of YB1, mTOR, AKT and p70S6K and the protein level of eEF1A1 were identified in HEG51 (i) and LEG110 (j) after HI-TOPK-032 treatment by Western blot. ‘C’ indicated vehicle group, ‘L’ indicated low treatment (5 mg/kg) group and ‘H’ indicated high treatment (10 mg/kg) group. All experiments were biological replicates and were repeated at least three times. Error bars showed standard error of the mean. *p ˂ 0.05, **p ˂ 0.01, ***p ˂ 0.001.

Back to article page